Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Scott Kuo"'
Autor:
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of tyrosine kinase inhibitor (TKI) tre
Externí odkaz:
https://doaj.org/article/bce3fbab037c45f29c24a461f2f07a28
Autor:
Chen‐Te Wu, Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2548-2557 (2023)
Abstract Background This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer. Methods The clinical featu
Externí odkaz:
https://doaj.org/article/fc07701970254cbbb9979c7ef0d94271
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Autor:
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR -mutant non-small-cell lung cancer. We
Externí odkaz:
https://doaj.org/article/cb59f58b72a54d5aa11a70e91bdabd7a
Autor:
John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 4, Pp 348-356 (2023)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse
Externí odkaz:
https://doaj.org/article/0d49cc0b61db45fda87814ded7764b7b
Autor:
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 12-23 (2023)
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGF
Externí odkaz:
https://doaj.org/article/34e2b99597da430da22ea8c1cd7a1a29
Autor:
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 13, Pp 1888-1897 (2022)
Abstract Background This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). Methods Patients diagnosed with de novo T790M+ NSCLC and treated with
Externí odkaz:
https://doaj.org/article/3fb18d1476c941f1b93a00a6782c7da0
Autor:
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) patients was lacking. 310 patients of advanced NSCLC with common EGFR mutati
Externí odkaz:
https://doaj.org/article/17eff21402b64752921f6d7b503a59e8
Autor:
How-Wen Ko, Shian-Sen Shie, Chih-Wei Wang, Chi-Tsun Chiu, Chih-Liang Wang, Tsung-Ying Yang, Shou-Chu Chou, Chien-Ying Liu, Chih-Hsi Scott Kuo, Yu-Ching Lin, Li-Fu Li, Cheng-Ta Yang, Chin-Chou Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionUncommon epidermal growth factor receptor (EGFR) mutations include single and complex mutations. However, the association of the smoking status of patients with uncommon and complex EGFR mutations remains unclear.MethodsThis retrospective
Externí odkaz:
https://doaj.org/article/60e77fceed284195934ae4d23d503e47
Autor:
Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Chiao-En Wu
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 16 (2022)
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) patients. Osimertinib is an effective therapy for NSCLC patients with acquire
Externí odkaz:
https://doaj.org/article/00f4c4be18244e979f2f334047c74e95
Autor:
Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥
Externí odkaz:
https://doaj.org/article/2a21b7e1de6043ccacddcea2f33a56a0